Teva Sees Disappointing Results in Copaxone Study
The 40-mg version of Teva’s blockbuster multiple sclerosis drug Copaxone did not demonstrate increased efficacy compared with a 20-mg dose, according to data from a Phase III trial.
The 1,155-patient, randomized, double-blind Copaxone (glatiramer acetate) study was conducted in 136 centers in North America, Argentina, Europe and Israel to measure the rate of confirmed relapses in subjects receiving the 20- or 40-mg version of the drug.
Of those treated with the 20-mg version, 78 percent remained relapse-free throughout the study. Patients who completed one year of treatment with the 20-mg dose experienced an annual relapse rate of 0.27 and a reduction of inflammatory activity as measured by an MRI, according to Teva.
While the 40-mg dose did not demonstrate increased efficacy in reducing the relapse rate, it maintained the favorable safety and tolerability profile of the lower dosage.